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Introduction
This year’s symposium was dominated by the results of
recent clinical trials. After 10 years of ‘magic bullet’ trials
in sepsis, a number of successful therapeutic options are
now emerging. In addition, recent advances in our under-
standing of the soup of mediators observed in sepsis offer
yet more tantalizing targets for new therapies.
In contrast, the eagerly awaited results from Italy of the
prone positioning trial in ARDS were disheartening. The
epidemiology of both sepsis and ARDS, and their impact
on clinical studies and the future provision of critical care
were also hot topics. The era of extracorporeal liver
replacement therapy is upon us, with considerable early
promise and the probability of wide availability. Finally, as
always, ethics remained an area of interest.
This report summarizes and discusses the presentations
on the above topics.
Sepsis
Angus (Pittsburgh, PA, USA) presented his group’s work
on the epidemiology of sepsis in the USA (accepted for
publication in Critical Care Medicine). They developed a
method for identifying hospitalized patients with sepsis
based on ICD9 criteria, the most widely recorded coding
system used in US hospitals. Prospective testing of the
method found it to be both sensitive and reliable. They
then applied it to a representative selection of US hospi-
tals. Their results indicated that about 50% of intensive
care unit (ICU) patients have systemic inflammatory
response syndrome, and that approximately 20% of these
progress to severe sepsis. Mortality for severe sepsis was
greater than 30%. Demographically, those at the extremes
of age represent the most at-risk groups, in whom the
mortality is also the highest. These data provides yet
another reminder that the increasing demands on health
care resources caused by the ageing population is pre-
dicted to exceed intensive care provision within the next
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10–20 years. Finally, those investigators found a striking
demographic peak in patients aged 20–30 years, which
they attributed largely to human immunodeficiency virus.
The long-standing debate between the two schools of
sepsis theory – microcirculatory dys-autoregulation
versus cellular dysfunction – shows signs of resolution.
New techniques for studying tissue oxygen tension, pre-
sented by Ince (Amsterdam, The Netherlands), provide
more evidence that microcirculatory dys-autoregulation
results in significant shunting. This occurs predominantly
in the submucosal and serosal portions of organs, and is
an early event. These studies show that the macroscopic
restoration of global oxygen delivery fails to improve
oxygen consumption as the mucosa becomes hyperoxic,
whereas the submucosa and serosa remain hypoxic.
Somewhat counterintuitively, this can be reversed in the
face of resistant hypotension with vasodilators, at least in
animal models.
The cellular dysfunction camp, although still somewhat
doubtful as to the importance of these microcirculatory
findings, have now clearly established that their champi-
oned mechanism of mitochondrial failure is a late but
crucial event in the evolution of sepsis. Fink (Pittsburgh,
PA, USA) presented evidence that mitochondrial failure in
septic cells is triggered by the activation of the enzyme
poly-adenosine diphosphate ribose polymerase [1]. This
enzyme represents a significant target for novel therapies,
which are apparently already in development. The debate
regarding the toxicity of oxygen and the formation of free
radicals continues despite the absence of demonstrated
effectiveness of scavenging therapies, and is a testament
to the incomplete understanding of this area.
The round-table conference preceding this year’s sympo-
sium concentrated on distilling current knowledge on the
microscopic events in critically ill patients into an explana-
tion of the macroscopic multiorgan failure that is so com-
monly encountered. The conclusions of the conference
appeared to relate mostly to future directions for research,
in particular the study of organ–organ interactions. Mar-
shall (Toronto, Canada) proposed the development of an
alternative to the much-maligned physiological scoring
systems, based on the staging systems widely used in the
field of oncology. He proposed that mediator levels, in
addition to physiological variables, will soon be used use-
fully to characterize septic patients. He also suggested
that, in the light of the recent successful mediator trials in
sepsis, future therapies will be directed in a manner analo-
gous to the control of glucose in diabetic patients.
The natural anticoagulants antithrombin III (AT III), tissue
factor pathway inhibitor (TFPI) and activated protein C
(APC), and the cytokine tumour necrosis factor (TNF)-a
are the latest inflammatory mediators to be targeted in
large multicentre clinical trials in an attempt to improve the
current dismal outcome for patients with severe sepsis.
The KyberSept AT III study recruited over 2300 patients
from 200 centres, with high Simplified Acute Physiology
Scale scores (median 50), and a mortality of nearly 40%
[2]. Unfortunately, no overall benefit was shown between
AT III and placebo, although results were more encourag-
ing in an analysis of the subgroup of patients who
received AT III but no heparin, which is known to inhibit AT
III. Interestingly, improvements in quality of life scores were
seen in survivors who received AT III in comparison to
those who received placebo, suggesting that morbidity
may be reduced, although again this was an analysis of a
subgroup. Patients in the AT III group who received con-
comitant heparin had a significantly higher incidence of
bleeding events, and outcome worsened as the dose of
heparin increased. Explanations for the failure of this study
included the inhibitory effects of heparin and the failure to
achieve AT III activity levels of greater that 200% from
baseline in the treatment population, a level established as
required for therapeutic benefit in phase II trials.
Phase II clinical trial results using TFPI (TFPI n = 141,
placebo  n = 69; unpublished data) show a mortality
benefit in the sicker sepsis patients who already have
coagulation problems. Results of the phase III multicentre
study are expected to be presented at the 22nd Interna-
tional Symposium on Intensive Care and Emergency Medi-
cine, in Brussels in 2002.
Human trials of various anti-TNF-a formulations have been
variable to date, and include North American sepsis trial
(NORASEPT) I [3], International sepsis trial (INTERSEPT)
[4] and NORASEPT II [5]. Possible reasons have included
a lack of biological activity of the anti-TNF-a formulation
studied, inappropriate timing of therapy, redundancy of
proinflammatory mediators and hetereogeneity of patient
populations. The Monoclonal Anti-TNF, A Randomized
controlled Sepsis Trial (MONARCS) study used a differ-
ent anti-TNF-a formulation (F[ab¢]2 fragment of a murine
monoclonal antibody to human TNF-a), and stratified
patients based on demonstrable abnormalities in immuno-
logical pathways (highly elevated interleukin-6 levels – a
circulating cytokine that is induced by TNF-a). Unpub-
lished results revealed 28-day mortality rates of 44 and
48% in the anti-TNF-a and placebo groups, respectively,
in those patients who had high interleukin-6 levels on
recruitment to the study (n = 488 anti-TNF-a,  n = 510
placebo). This represented a relative mortality reduction of
14%. Relative mortality reduction in all patients (n = 1305
anti-TNF-a,  n = 1329 placebo), independent of baseline
interleukin-6 levels, was only 10%.
The Recombinant Human Activated Protein C Worldwide
Evaluation in Severe Sepsis (PROWESS) study is hot offCritical Care    Vol 5 No 3 Ball and Venn
the press [6], and presentation of the results at the con-
gress allowed those of us who still carry the unopened
New England Journal of Medicine issue in our briefcases
to catch up! A total of 164 sites from 11 countries
recruited 1690 patients with severe sepsis, before the trial
was prematurely stopped following the second safety
analysis. Twenty-eight-day all-cause mortality rates for
placebo and APC were 31 and 25% respectively, with a
relative risk reduction of 19%. Resolution of cardiovascu-
lar and respiratory function was more rapid in survivors
who received APC, although ICU and hospital stay did not
differ. There was a trend towards an increase in serious
bleeding events in the APC group (3% APC versus 2%
placebo), but these events were primarily due to trauma or
instrumentation. Although this is an exciting breakthrough,
we all recognize that when APC reaches the market place
it will seriously stretch ICU finances, especially because
there appear to be other mediators on the horizon that we
will be encouraged to use, in combination, to fight the
inflammatory ‘soup’.
Acute respiratory distress syndrome 
Two opposing epidemiological views of ARDS were pre-
sented by Lemaire (Créteil, France) and Evans (London,
UK). Broad agreement does seem to exist as to the inci-
dence of this condition, which is in the order of
10/100,000, although there is significant variation
between countries. It was argued that this variation results
from the availability of ventilated beds, with higher inci-
dences apparent in countries with greater provision,
emphasizing that this condition can be considered the
result of intensive care intervention or, as one speaker put
it, ‘physician-induced lung injury’.
Early results from the Acute Lung Injury Verification of
European Epidemiology (ALIVE) study (unpublished data),
sponsored by the European Society of Intensive Care
Medicine, are at odds with recent trial findings. The ALIVE
study, which included over 6000 patients surveyed in
1998, found a 50–60% 28-day mortality, which compares
to only 20–30% in the control groups of recent trials.
Pneumonia was the commonest cause, responsible for
50% of cases, with sepsis identified as the cause in a
further 20–30%. Astonishingly, this study found the ratio
of arterial oxygen tension to fractional inspired oxygen at
ICU admission was highly predictive of mortality, despite
continuing controversy regarding this measurement.
A diverse range of views were presented from the Third
International Consensus Conference on ARDS (unpub-
lished data), held in Barcelona late last year. The decision
as to how to change the defining criteria for this condition
remains unresolved. The debates surrounding chest X-ray
criteria, the use of the ratio of arterial oxygen tension to
fractional inspired oxygen, and the level/utility of pul-
monary artery wedge pressure measurements continue.
In addition, a debate has arisen as to whether ARDS can
be a unilateral process, and whether it can coexist with
cardiac failure. There appears to be increasing recogni-
tion that ARDS represents only a small subset of patients
with acute lung failure (approximately 30%). Surprisingly
little is known about the remainder of this larger group. In
contrast to the ALIVE study, several centres have
reported their 28-day mortality at 40%, which represents
an improvement from the 60% of 10 years ago. However,
it was argued that a 28-day follow-up period is too short
for clinical trials, as the long-term quality of life for
patients with ARDS is poor compared with that of criti-
cally ill patients without this condition. Results suggest
that the recovery of lung function is good overall, but is
dependent on severity. Treatment recommendations
include the universal adoption of the US National Insti-
tutes of Health protective lung ventilation strategy [7].
There was general agreement that recruitment manoeu-
vres are beneficial, but how and when to employ them
remains controversial.
Rouby (Paris, France) put forward a new classification for
ARDS based on computed tomography findings. He
observed that patients can be split into three groups,
depending on the appearance of the upper lobes. In group
1 the upper lobes are normal, and positive end-expiratory
pressure (PEEP) is of little benefit and results in significant
over-distension. Survival in this group is approximately
60%. In group 2 the upper lobes are abnormal, PEEP is of
dramatic benefit, but survival is only  approximately 25%.
In group 3 there are mixed/patchy abnormalities, the
effects of PEEP are less predictable, but, as in group 1,
survival is approximately 60%.
Gattinoni (Milan, Italy) presented the results of the long-
awaited Italian multicentre randomized controlled trial of
prone positioning in ARDS (unpublished data). This trial
was terminated after 3 years despite having only recruited
304 patients; enrollment of 750 patients was originally
planned, in order to achieve sufficient statistical power. At
trial outset, recruitment was encumbered by the lack of
familiarity with and scepticism regarding this procedure in
many of the centres. However, by the end of the study
many participants were unwilling to enter patients into the
trial, because they felt it unethical to deny them this inter-
vention. The trial protocol resulted in patients in the treat-
ment group being prone for an average of only 7 out of
24 h for a 10-day period. Overall there was no difference
in mortality between the control and treatment groups at
day 10, time of ICU discharge, or at 6 months. Interest-
ingly, analysis of subgroups revealed a significant differ-
ence in the outcome at 10 days for patients with the most
severe disease, although this disappeared by ICU dis-
charge. In retrospect, the design of this ambitious trial was
flawed by its failure to establish the optimal utilization of
this manoeuvre.Available online http://ccforum.com/content/5/3/138
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Extracorporeal techniques for liver failure
The opening session reported that we are making
progress in supporting the failing liver (Wendon, London,
UK). Current optimism should probably be limited to extra-
corporeal methods, because the molecular adsorbent
recirculating system (essentially extracorporeal albumin
dialysis) has been shown to have beneficial clinical effects
as well as improved survival in two small randomized con-
trolled trials [8,9]. The equipment is familiar to all those
who use dialytic therapies, and we will undoubtedly hear
more about this system in the next few years.
Noninvasive mechanical ventilation
The slide of a patient reading the newspaper through a
transparent helmet, while receiving noninvasive ventila-
tion (NIV) resembled pictures of a NASA astronaut!
However, it was reported to be well tolerated for pro-
longed periods, and significantly reduces the complica-
tions associated with NIV (pressure areas, tolerance of
mask). The recent Consensus Conference [10] exam-
ined weaning aspects of NIV and emphasized the
reduced weaning time and avoidance of reintubation, but
called for more randomized controlled trials. Finally,
although continuous positive airway pressure has been
shown to be beneficial in pulmonary oedema, caution is
still advised with the use of bilevel positive airway pres-
sure because of the reporting of myocardial infarction in
several studies. However, the groups studied were
unmatched and starting points were different, so conclu-
sions should not be drawn until randomized controlled
trial results are available in this area.
Ethics
This was a well-attended session, which, according to
Levy (Providence, RI, USA), was in complete contrast to
the interest shown in the USA for the subject. Although
there were few new data in the session, the emphasis on a
strategy for lawsuits was welcome. Suggestions included
statements from scientific societies at a national and inter-
national level, open reporting in medical files of decisions
to withdraw or withhold treatment, and family involvement
in decision making that will ultimately involve better media
education.
Conclusion
The last day of this year’s symposium was sadly aban-
doned by many due to the Belgian rail strike. Despite this,
the usual convivial atmosphere, both in and around the
congress, was as abundant as ever. Overall, the ‘state of
the art’ lectures, pro/con debates, seminars and tutorials
were of the usual high standard, although, yet again,
access to many of the symposium’s venues was limited by
the lack of capacity of the secondary rooms. The 21st
International Symposium was marked by a sense of
renewed enthusiasm that real positive progress is occur-
ring at the coal face of intensive care.
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